Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights

 
• By Emily Hayes

Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.

CD38_Enzyme_642347347.jpg
Phase III data for J&J's Darzalex in frontline multiple myeloma will be a highlight of a late-breaker session at the ASH meeting. Above, 3D rendering of the CD38 (ectodomain fragment) enzyme, the target of Darzalex.

More from Clinical Trials

More from R&D